Zafrens has secured a $23M funding led by Prime Movers Lab, additional investors include; BlueYard Capital, KOFA Healthcare, Global Brains, FoundersX Ventures, Alix Ventures, Possible Ventures, Iaso Ventures, and Hawktail.

Zafrens is looking to engage with partners in its internal areas of expertise rapid, HLA-independent, highly-selective TCR discovery, and RNA regulatory small molecules across 3' UTR regulation, splicing and epigenetic reprogramming.